Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab and AUY922 in HER2-positive advanced NSCLC
DRKS00003301Phase 2Terminated
- Sponsor
- University of Cologne
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, Luminespib in non-small cell lung cancer (NSCLC), sponsored by University of Cologne. Started Nov 2012; status: terminated.
02
Drugs
trastuzumabLuminespib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on DRKS00003301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003301.